Skip to content
Home/Companies/Biotech/Quince Therapeutics (formerly EryDel)
QT

Quince Therapeutics (formerly EryDel)

Biotech·US·Active·7yr hold

Quince Therapeutics (formerly EryDel) is a healthcare / biotech company, headquartered in United States.

Entry
2019
Hold
7yr
Status
Active
Est. EV
–

Who owns Quince Therapeutics (formerly EryDel)?

Quince Therapeutics (formerly EryDel) is currently owned by Sofinnova Partners through Sofinnova Capital IX (2018 vintage), since 2019.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQUnited States
SectorHealthcare / Biotech

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
Active
MedTechUS· 2020
Genespire
Active
BiotechItaly· 2020
Nitrase Therapeutics
Active
BiotechUS· 2020
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to
Pi-Cardia
Active
MedTechIsrael· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings